Development of Targeted Antibody Therapy to Reduce Antimicrobial Resistance-Related Morbidity and Mortality in the Erasmus Medical Centre

Recruiting

• Conditions: blood poisoning; 10004018

• Registration Number: NL-OMON44672
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Aged between 18- years and 65 years
Diagnosed with sepsis and with a positive blood culture for E. coli or P. aeruginosa
Signed informed consent by the patient or his/her legal representative

Exclusion Criteria

Age younger than 18 years
Age older than 65 years
Receiving immunosuppressive medication, including chemotherapy
HIV seropositivity
Hematological malignancies

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary objective of the study is the cloning of recombinant antibodies<br /><br>against E. coli and P. aeruginosa to develop antibody therapy for patients<br /><br>suffering from nosocomial infections, including patients that are<br /><br>immunocompromised and have a reduced cellular immune response.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To obtain new insights into the nature of the immune response to E. coli and P.<br /><br>aeruginosa infections.</p><br>